eISSN : 2146-9369
Creative Commons Lisansı
Journal of Clinical and Experimental Investigations is licenced under the terms of Creative Commons Attribution-Non Commercial4.0 International (CC BY-NC 4.0) License.
Abstract - Identification of Novel Vaccine Candidates against Yellow Fever Virus from the Envelope Protein: An insilico Approach
Hind Abdelrahman Hassan, Khoubieb Ali Abd-elrahman, Nasr Mohammed Nasr, Yassir A. Almofti

Identification of Novel Vaccine Candidates against Yellow Fever Virus from the Envelope Protein: An Insilico Approach

Hind Abdelrahman Hassan1,2, Khoubieb Ali Abdelrahman3, Nasr Mohammed Nasr1,2, Yassir A. Almofti1

1Department of Molecular Biology and Bioinformatics, College of Veterinary Medicine, University of Bahri, Khartoum, Sudan

2Department of Microbiology, College of Medical laboratory Science, Omdurman Ahlia University, Omdurman, Sudan

3Department of Pharmaceutical Technology, College of Pharmacy, University of Medical Science and Technology, Khartoum- Sudan



Objectives: Yellow fever virus (YFV) is an enveloped positive sense RNA virus. It is the causative agent of the mosquito-borne disease yellow fever. The aim of this study was to design multi epitopes vaccine for YFV from envelope protein eliciting humoral and cellular immunity.

Methods: Twenty six YFV strains envelope proteins were retrieved from NCBI. The immune epitope database analysis resources (IEDB) were used for epitopes prediction.

Results: Eleven epitopes successfully passed all B cell prediction tools, among them four epitopes 33VMAPDKPSL41, 72DKCP77, 236PPHA239 and 385LTYQ388 demonstrated higher score in Emini and Kolaskar and tongaonker software. Thus were proposed as B cells epitopes. For T cells; 28 epitopes interacted with MHC-I and the best recognizable epitopes were 471MTMSMSMIL479, 363VLIEVNPPF371, 33VMAPDKPSL41 and 226REMHHLVEF234. For MHC-II ninety epitopes were predicted and the best epitopes were 284RVKLSALTL292, 363VLIEVNPPF371, 479LVGVIMMFL487 and 226REMHHLVEF234. Strikingly the epitope 33VMAPDKPSL41 successfully interacted with both B and T cells. Also 363VLIEVNPPF371 and 226REMHHLVEF234 demonstrated successful interaction with T cells. The population coverage was 84.66% and 99.91% for MHC-I and MHC-II epitopes, respectively, and 99.99% for all T cells epitopes.

Conclusions: Taken together nine epitopes successfully proposed as vaccine candidate against YFV. In vivo and in vitro clinical trials studies are required to elucidate the effectiveness of these epitopes as vaccine. J Microbiol Infect Dis 2020; 10(1):31-46.

Keywords: Yellow fever virus; NCBI; IEDB; Immunoinformatics; Insilico vaccine

Volume 10, Number 01 (2020)